​

Pfizer (PFE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PFE Stock Forecast

Pfizer (PFE) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $29.67, with a high of $33.00 and a low of $24.00. This represents a 28.72% increase from the last price of $23.05.

$23 $25 $27 $29 $31 $33 High: $33 Avg: $29.67 Low: $24 Last Closed Price: $23.05

PFE Stock Rating

Pfizer stock's rating consensus is Hold, based on 32 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (40.62%), 18 Hold (56.25%), 1 Sell (3.12%), and 0 Strong Sell (0.00%).

Hold
Total 32 1 18 13 Strong Sell Sell Hold Buy Strong Buy

PFE Price Target Upside V Benchmarks

TypeNameUpside
StockPfizer28.72%
SectorHealthcare Stocks 31.82%
IndustryDrug Manufacturers - General Stocks32.54%

Price Target Trends

1M3M12M
# Anlaysts1111
Avg Price Target$24.00$24.00$32.09
Last Closing Price$23.05$23.05$23.05
Upside/Downside4.12%4.12%39.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2536131-23
Mar, 2536131-23
Feb, 2537131-24
Jan, 2538131-25
Dec, 2438131-25
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 22, 2025Carter GouldCantor Fitzgerald$24.00$22.536.52%4.12%
Dec 18, 2024Robyn KarnauskasTruist Financial$32.00$25.8923.60%38.83%
Oct 30, 2024Chris ShibutaniGoldman Sachs$33.00$28.4615.95%43.17%
Oct 17, 2024Courtney BreenBernstein$32.00$29.677.85%38.83%
Sep 25, 2024Carter GouldBarclays$32.00$28.9310.61%38.83%
Aug 07, 2024Narumi NakagiriDaiwa$34.00$28.8517.85%47.51%
Jul 31, 2024Mohit BansalWells Fargo$30.00$31.39-4.43%30.15%
Jul 31, 2024Chris ShibutaniGoldman Sachs$34.00$31.398.31%47.51%
Jul 30, 2024Vamil DivanGuggenheim$36.00$30.7217.19%56.18%
Jul 10, 2024Carter GouldBarclays$30.00$27.728.23%30.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 22, 2025Cantor FitzgeraldOverweightNeutralinitialise
Mar 27, 2025CitigroupNeutralNeutralhold
Feb 28, 2025UBSNeutralNeutraldowngrade
Oct 30, 2024Goldman SachsBuyBuyhold
Oct 23, 2024Wells FargoMarket PerformMarket Performhold
Oct 17, 2024BernsteinMarket Performinitialise
Sep 25, 2024BarclaysEqual-WeightEqual-Weighthold
Sep 20, 2024Wells FargoEqual-WeightEqual-Weighthold
Sep 13, 2024BMO CapitalOutperformOutperformhold
Jul 31, 2024Wells FargoEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.26$3.95$5.59$0.38$1.42----
Avg Forecast$2.83$4.21$6.50$1.55$2.92$2.91$3.01$2.98$2.85
High Forecast$2.93$4.35$6.64$1.66$3.12$3.03$3.92$3.37$2.91
Low Forecast$2.73$4.06$6.29$1.48$2.73$2.46$2.58$2.24$2.77
Surprise %-55.48%-6.18%-14.00%-75.48%-51.37%----

Revenue Forecast

$40B $53B $66B $79B $92B $105B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$41.91B$81.29B$100.33B$58.50B$63.63B----
Avg Forecast$48.20B$81.76B$100.34B$58.78B$63.08B$63.08B$63.06B$62.33B$59.90B
High Forecast$49.46B$83.89B$101.97B$59.18B$63.63B$63.93B$63.14B$62.50B$60.82B
Low Forecast$46.90B$79.56B$97.80B$58.53B$62.67B$62.46B$62.99B$62.17B$58.66B
Surprise %-13.06%-0.58%-0.01%-0.48%0.87%----

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.02B$21.98B$31.37B$2.12B$8.03B----
Avg Forecast$8.71B$24.02B$18.44B$2.13B$16.71B$15.66B$18.56B$12.93B$16.27B
High Forecast$10.45B$24.84B$22.12B$2.56B$17.81B$17.30B$22.37B$19.23B$16.59B
Low Forecast$6.97B$23.18B$14.75B$1.71B$15.60B$14.02B$14.75B$12.79B$15.83B
Surprise %-19.40%-8.52%70.16%-0.70%-51.94%----

PFE Forecast FAQ

Is Pfizer stock a buy?

Pfizer stock has a consensus rating of Hold, based on 32 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 18 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Pfizer is a neutral investment for most analysts.

What is Pfizer's price target?

Pfizer's price target, set by 32 Wall Street analysts, averages $29.67 over the next 12 months. The price target range spans from $24 at the low end to $33 at the high end, suggesting a potential 28.72% change from the previous closing price of $23.05.

How does Pfizer stock forecast compare to its benchmarks?

Pfizer's stock forecast shows a 28.72% upside, underperforming the average forecast for the healthcare stocks sector (31.82%) and underperforming the drug manufacturers - general stocks industry (32.54%).

What is the breakdown of analyst ratings for Pfizer over the past three months?

  • April 2025: 13.04% Strong Buy, 26.09% Buy, 56.52% Hold, 4.35% Sell, 0% Strong Sell.
  • March 2025: 13.04% Strong Buy, 26.09% Buy, 56.52% Hold, 4.35% Sell, 0% Strong Sell.
  • February 2025: 12.50% Strong Buy, 29.17% Buy, 54.17% Hold, 4.17% Sell, 0% Strong Sell.

What is Pfizer’s EPS forecast?

Pfizer's average annual EPS forecast for its fiscal year ending in December 2025 is $2.91, marking a 104.93% increase from the reported $1.42 in 2024. Estimates for the following years are $3.01 in 2026, $2.98 in 2027, and $2.85 in 2028.

What is Pfizer’s revenue forecast?

Pfizer's average annual revenue forecast for its fiscal year ending in December 2025 is $63.08B, reflecting a -0.86% decrease from the reported $63.63B in 2024. The forecast for 2026 is $63.06B, followed by $62.33B for 2027, and $59.9B for 2028.

What is Pfizer’s net income forecast?

Pfizer's net income forecast for the fiscal year ending in December 2025 stands at $15.66B, representing an 94.99% increase from the reported $8.03B in 2024. Projections indicate $18.56B in 2026, $12.93B in 2027, and $16.27B in 2028.